AcelRx Pharmaceuticals, Inc.:
Launched DSUVIA (sufentanil sublingual tablet 30 mcg) in the US in 1Q19 for acute pain severe enough to require opioid analgesic (adult patients in certified medically supervised healthcare settings). In 3Q19 reported 130 REMS-certified healthcare facilities & 105 formulary approvals. Also developing Zalviso (Ph 3 completed) in the US as an innovative patient-controlled analgesia system for moderate-to-severe acute pain in medically supervised settings.
US - Pacific
Phase III, Registration Stage
Biotechnology, Medical Device, Specialty Pharmaceutical
100MM - 500MM
351 Galveston Drive
Redwood City, CA 94063
Top 10 Holders of AcelRx Pharmaceuticals, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by